Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

41. Causes and risk factors: Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence

Causes and risk factors: Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence Article Text Electronic pages Causes and risk

2017 Evidence-Based Mental Health

42. Vitamin levels in adults with ADHD (PubMed)

Vitamin levels in adults with ADHD Micronutrients containing vitamins are reported to reduce symptom levels in persons with attention-deficit hyperactivity disorder (ADHD), but data on vitamin levels in ADHD are sparse.To examine the relationship between vitamin concentrations, ADHD diagnosis and psychiatric symptoms in young adult ADHD patients and controls.Eight vitamins and the nicotine metabolite cotinine were analysed in serum samples from 133 ADHD patients and 131 controls aged between 18 (...) and 40, who also reported ADHD symptoms and comorbid conditions.Lower concentrations of vitamins B2, B6 and B9 were associated with the ADHD diagnosis, and B2 and B6 also with symptom severity. Smokers had lower levels of vitamins B2 and B9.ADHD patients were overrepresented in the group with low levels of some vitamins, possibly indicative of inadequate dietary intake of these micronutrients in a subgroup of patients. It is important to identify these patients in dietary intervention trials

Full Text available with Trip Pro

2016 BJPsych open

43. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivity disorder (ADHD).We identified relevant studies and classified them using American Academy of Neurology criteria.Two Class I studies assessing the ability of EEG theta (...) /beta power ratio and EEG frontal beta power to identify patients with ADHD correctly identified 166 of 185 participants. Both studies evaluated theta/beta power ratio and frontal beta power in suspected ADHD or in syndromes typically included in an ADHD differential diagnosis. A bivariate model combining the diagnostic studies shows that the combination of EEG frontal beta power and theta/beta power ratio has relatively high sensitivity and specificity but is insufficiently accurate.It is unknown

Full Text available with Trip Pro

2016 EvidenceUpdates

44. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. (PubMed)

Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%.To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children.In a 6-week double (...) -blind clinical trial, the efficacy of Risperidone 0.5-2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3-6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners' Parent Rating Scale (CPRS-48), Children's Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher's exact tests in the SPSS 19

Full Text available with Trip Pro

2016 Electronic physician

45. Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. (PubMed)

Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. 26429338 2016 08 24 2018 12 02 1468-960X 18 4 2015 Nov Evidence-based mental health Evid Based Ment Health Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. e9 10.1136/eb-2015-102151 Rockhill Carol C Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA

2016 Evidence-Based Mental Health

46. Omega-6 to Omega-3 Fatty Acid Ratio in Patients with ADHD: A Meta-Analysis. (PubMed)

Omega-6 to Omega-3 Fatty Acid Ratio in Patients with ADHD: A Meta-Analysis. Omega-3 and omega-6 fatty acids have been shown to be deficient in individuals with attention deficit/hyperactivity disorder compared to controls (Hawkey & Nigg, 2014). Clinical trials of omega-3 and omega-6 supplements as treatment for ADHD have demonstrated minimal efficacy (Bloch & Qawasmi, 2011; Gillies, Sinn, Lad, Leach, & Ross, 2011; Hawkey & Nigg, 2014; Puri & Martins, 2014; Sonuga-Barke et al., 2013). Existing (...) trials have analyzed omega-3 and omega-6 separately although the tissue ratio of these fatty acids (n6/n3) may be more important than absolute levels of either. The objective of this study was to determine the relationship between blood n6/n3 and arachidonic acid to eicosapentaenoic acid (AA/EPA), to ADHD symptoms.A systematic literature review identified original articles measuring blood n6/n3 or AA/EPA ratio in children and youth with ADHD, compared to controls without ADHD. Three databases were

Full Text available with Trip Pro

2016 Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent

47. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. (PubMed)

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.  To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Self controlled case series analysis. Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. 1224 patients aged (...) in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly

Full Text available with Trip Pro

2016 BMJ

48. Pharmacologic Management of Patients with ADHD: Review of Guidelines

Pharmacologic Management of Patients with ADHD: Review of Guidelines Pharmacologic Management of Patients With ADHD: Review of Guidelines | CADTH.ca Find the information you need Pharmacologic Management of Patients With ADHD: Review of Guidelines Pharmacologic Management of Patients With ADHD: Review of Guidelines Published on: March 18, 2016 Project Number: RC0759-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What (...) are the evidence-based guidelines for the pharmacologic management of ADHD in children, adolescents, and adults? Key Message Stimulant drugs are the first-choice pharmacological treatment for ADHD in children, adolescents, and adults. Atomoxetine is the preferred initial choice of treatment when there is a risk that stimulant drugs may be abused/misused or diverted. Atomoxetine is also the recommended drug of choice when stimulant ADHD drugs are contra-indicated, ineffective, or poorly tolerated

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

49. The challenges of implementing ADHD clinical guidelines and research best evidence in routine clinical care settings: Delphi survey and mixed-methods study (PubMed)

The challenges of implementing ADHD clinical guidelines and research best evidence in routine clinical care settings: Delphi survey and mixed-methods study The landmark US Multimodal Treatment of ADHD (MTA) study established the benefits of individualised medication titration and optimisation strategies to improve short- to medium-term outcomes in attention-deficit hyperactivity disorder (ADHD). This individualised medication management approach was subsequently incorporated into the National (...) Institute for Health and Care Excellence (NICE) ADHD Clinical Guidelines (NICE CG78). However, little is known about clinicians' attitudes towards implementing these medication management strategies for ADHD in routine care.To examine National Health Service (NHS) healthcare professionals' consensus on ADHD medication management strategies.Using the Delphi method, we examined perceptions on the importance and feasibility of implementing 103 ADHD treatment statements from sources including the UK NICE

Full Text available with Trip Pro

2016 BJPsych open

50. Outcomes: Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity

Outcomes: Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity Article Text Electronic pages Outcomes Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity Joel Nigg

2016 Evidence-Based Mental Health

51. Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Article Text Perspective Methylphenidate for ADHD in children and adolescents: throwing the baby out

Full Text available with Trip Pro

2016 Evidence-Based Mental Health

52. Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality?

Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ Article Text Perspective Evidence on methylphenidate in children and adolescents with ADHD

Full Text available with Trip Pro

2016 Evidence-Based Mental Health

53. Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD)

Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD) Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD) - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD (...) ) Have you found an error? Order Download: Key message The Norwegian Institute of Public Health, Knowledge Centre was commissioned by “Bestillerforum RHF” to undertake a rapid review of research on Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD). Methods We conducted a systematic search in nine medical, social science and health-related databases to identify relevant research publications about adults with ADHD and psychoeducative treatment. The search was conducted

2016 Norwegian Institute of Public Health

54. ADHD in Children and Adolescents

ADHD in Children and Adolescents ADHD in Children and Adolescents -- Clinical Recommendation Welcome Search Search Specify your search AAFP.org Patient Care Clinical Practice Guideline ADHD in Children and Adolescents ADHD: Clinical Practice Guidelines for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (Reaffirmed, May 2016) The guideline on ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment (...) of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents was developed by the American Academy of Pediatrics (AAP) and endorsed by the American Academy of Family Physicians (AAFP). Key Recommendations Any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity should be evaluated for ADHD. The diagnosis of ADHD should be based on the criteria from the Diagnostic and Statistical Manual of Mental Disorders

2016 American Academy of Family Physicians

55. Practice advisory: the utility of eeg theta/beta power ratio in adhd diagnosis

Practice advisory: the utility of eeg theta/beta power ratio in adhd diagnosis Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share November 29, 2016 ; 87 (22) Special Article Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis Report of the Guideline Development (...) .), University of California at Los Angeles. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis David Gloss , Jay K. Varma , Tamara Pringsheim , Marc R. Nuwer Neurology Nov 2016, 87 (22) 2375-2379; DOI: 10.1212/WNL.0000000000003265 Citation Manager Formats Make Comment See Comments Downloads 2753 Share Abstract Objective: To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivity disorder (ADHD). Methods: We

2016 American Academy of Neurology

56. Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Final Appraisal Recommendation Advice No: 2615 – September 2015 Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) 30 mg, 50 mg and 70 mg hard capsules Submission by Shire Pharmaceuticals Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2534 (...) the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2615: Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) 30 mg, 50 mg and 70 mg hard capsules. September 2015. Recommendation of AWMSG Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

2015 All Wales Medicines Strategy Group

57. ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines

ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines (...) ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines Published on: September 15, 2015 Project Number: RC0701-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of switching to another ADHD medication for patients who experience aggression or mood changes secondary to therapy with methylphenidate

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

58. Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines

Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines | CADTH.ca Find the information you need Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Published on: September 3, 2015 Project Number: RB0905-000 Product Line: Research Type: Drug (...) Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence regarding methods of dosage delivery of attention deficit hyperactivity disorder (ADHD) medications to patients with swallowing difficulties? What are the evidence-based guidelines regarding method of dosage delivery of ADHD medications to patients with swallowing difficulties? Key Message One evidence-based guideline was identified regarding methods of dosage delivery of ADHD medications to patients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

59. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research

Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD)delivered in school settings: systematic reviews of quantitative and qualitative research Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page

Full Text available with Trip Pro

2015 NIHR HTA programme

60. Medical augmentation of labor and the risk of ADHD in offspring: a population-based study (PubMed)

Medical augmentation of labor and the risk of ADHD in offspring: a population-based study Oxytocin for labor augmentation is widely used in obstetric care in Western countries. Two recent, smaller studies found opposing results regarding the association between prenatal exposure to oxytocin for labor augmentation and attention-deficit/hyperactivity disorder (ADHD). In Denmark, oxytocin is the medication used for nearly all medical augmentations of labor, and we examined the association between (...) medical augmentation of labor and ADHD in a large cohort study based on national register data.All singletons born after spontaneous onset of labor in Denmark between 2000 and 2008 (N = 546 146) were included in the study. Data from the Danish Medical Birth Registry on medical augmentation of labor (yes/no) were used to identify exposed children. ADHD was defined based on the diagnostic codes of International Classification of Diseases, 10th Revision, for hyperkinetic disorder and information

Full Text available with Trip Pro

2015 EvidenceUpdates